A single centre, randomised controlled, open label study of rituximab as induction therapy in kidney transplantation

Submission date	Recruitment status Stopped	[X] Prospectively registered		
30/03/2005		☐ Protocol		
Registration date	Overall study status	Statistical analysis plan		
10/05/2005 Last Edited	Stopped Condition category	[X] Results		
		☐ Individual participant data		
19/09/2017	Surgery	Record updated in last year		

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Mr Christopher Watson

Contact details

Dept of Surgery Box 202 Addenbrooke's Hospital Cambridge United Kingdom CB2 2QQ

Additional identifiers

EudraCT/CTIS number 2005-001496-35

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

N/A

Study information

Scientific Title

A single centre, randomised controlled, open label study of rituximab as induction therapy in kidney transplantation

Acronym

Rituxicam2005

Study objectives

Primary objective: To evaluate the effect of rituximab compared to daclizumab on the incidence and severity of acute rejection

Secondary objectives:

To evaluate the effect of rituximab on patient and graft survival following transplantation To evaluate the differences in gene expression patterns in patients immunosuppressed with rituximab compared to daclizumab by microarray analysis

Ethics approval required

Old ethics approval format

Ethics approval(s)

Huntingdon Research Ethics Committee, ref 05/Q0104/144, date 19/12/2005.

Study design

Single centre randomised controlled open label study

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Not specified

Study type(s)

Not Specified

Participant information sheet

Health condition(s) or problem(s) studied

Immunosuppression following renal transplantation

Interventions

Comparision of rituximab with daclizumab as induction immunosuppression following renal transplantation

Added 01/02/2010: The trial was stopped prematurely due to an excess of acute rejection in the study arm.

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Rituximab, daclizumab

Primary outcome measure

- 1. Acute rejection incidence
- 2. Acute rejection severity Banff scale
- 3. Incidence of steroid resistant rejection, defined as the need for ATG therapy

Secondary outcome measures

- 1. Patient survival
- 2. Graft survival
- 3. Graft function estimated glomerular filtration rate (GFR)
- 4. Incidence of infection culture positive infections
- 5. Incidence of C4d+ endothelial staining together with infiltrate on renal biopsy
- 6. Incidence of anti-donor HLA-specific antibody in post transplant sera

Overall study start date

01/04/2006

Completion date

31/03/2014

Reason abandoned (if study stopped)

Objectives no longer viable

Eligibility

Key inclusion criteria

Patients undergoing renal transplantation

Participant type(s)

Patient

Age group

Adult

Sex

Both

Target number of participants

120

Key exclusion criteria

Age under 18 years

Date of first enrolment 01/04/2006

Date of final enrolment 31/03/2014

Locations

Countries of recruitment

England

United Kingdom

Study participating centre
Dept of Surgery
Cambridge
United Kingdom
CB2 2QQ

Sponsor information

Organisation

Cambridge University Hospitals NHS Foundation Trust (UK)

Sponsor details

Addenbrooke's Hospital Hills Road Cambridge England United Kingdom CB2 2QQ

Sponsor type

Hospital/treatment centre

ROR

https://ror.org/04v54gj93

Funder(s)

Funder type

Industry

Funder Name

Roche Products Limited (UK)

Funder Name

Cambridge Transplant Unit (UK)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	18/06/2009		Yes	No